Gilead Sciences, Inc. $GILD Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 104.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,667,799 shares of the biopharmaceutical company’s stock after purchasing an additional 850,906 shares during the period. Voya Investment Management LLC owned 0.13% of Gilead Sciences worth $186,877,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of GILD. Price T Rowe Associates Inc. MD increased its position in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. Nuveen LLC acquired a new position in Gilead Sciences during the first quarter worth approximately $620,415,000. GAMMA Investing LLC increased its position in Gilead Sciences by 13,891.1% during the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock worth $285,761,000 after purchasing an additional 2,532,070 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in Gilead Sciences by 422.6% during the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after buying an additional 2,040,261 shares during the period. Finally, Royal Bank of Canada grew its stake in Gilead Sciences by 30.1% during the fourth quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company’s stock worth $801,655,000 after buying an additional 2,005,863 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the transaction, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. This represents a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock valued at $9,371,330. 0.27% of the stock is owned by insiders.

Gilead Sciences Price Performance

Shares of GILD stock opened at $117.86 on Friday. The company has a market capitalization of $146.24 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. The firm has a fifty day simple moving average of $113.97 and a 200-day simple moving average of $110.07. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $81.57 and a twelve month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is 62.95%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research note on Friday, August 8th. Finally, Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.